{"entity":{"id":"nct07217119","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM","aka":[],"tldr":"A phase 1/2 trial of Belantamab mafodotin in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.","summary":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM is a phase 1/2 interventional study registered as NCT07217119 by GlaxoSmithKline, with 25 participants enrolled, started 2019-11-26 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Feladilimab. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07217119","url":"https://clinicaltrials.gov/study/NCT07217119"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["belantamab-mafodotin","feladilimab"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07217119","phase":"1/2","setting":"A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 2 - Belantamab Mafodotin and Feladilimab (GSK3359609) in Combination","sponsor":"GlaxoSmithKline","started":"2019-11-26","startedType":"actual","yearReported":2026,"enrolled":25,"enrolledBasis":"registry","outcomes":[{"endpoint":"Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLTs)","primary":true,"unit":"participants","arms":[{"name":"1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab","n":9,"value":1,"note":"Figures from the ClinicalTrials.gov results section (first posted 2026-06-25), not from a publication"},{"name":"2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab","n":10,"value":1},{"name":"2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab","n":6,"value":0}],"source":"https://clinicaltrials.gov/study/NCT07217119?tab=results"},{"endpoint":"DE Phase: Overall Response Rate (ORR)","unit":"%","arms":[{"name":"1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab","n":9,"value":44,"note":"95% CI 13.7 to 78.8; Figures from the ClinicalTrials.gov results section (first posted 2026-06-25), not from a publication"},{"name":"2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab","n":10,"value":50,"note":"95% CI 18.7 to 81.3"},{"name":"2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab","n":6,"value":67,"note":"95% CI 22.3 to 95.7"}],"source":"https://clinicaltrials.gov/study/NCT07217119?tab=results"}]},"route":"/trials/nct07217119/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"},{"id":"feladilimab","kind":"drug","name":"Feladilimab","route":"/drugs/feladilimab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}